Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency... see more

TSX:MBX - Post Discussion

View:
Comment by RazeKreations on Dec 29, 2021 12:01pm
She did her analysis before the second order of VTM came in. I am sure that if it had been after her analysis would have been maintained or even slightly upgraded.
Comment by rjc7 on Dec 29, 2021 1:03pm
if that's the case she should correct it
Comment by RazeKreations on Dec 29, 2021 1:56pm
Notably, the reduced projections were on account of Ontario not having completed a reorder, which has since happened, though Stellick expects Ontario to be a significant contributor to revenue and gross profit in 2022, as demand for local supply of COVID-19 testing components is stronger than ever given ongoing supply chain issues. Overall, Stellick believes Microbix is executing on its growth ...more  
Comment by Mbxwatcher on Dec 29, 2021 2:49pm
In my opinion this is a half-assed article. She maintained her buy rating, and the $1.70 target. Why would she do that if everything is so seriously downgraded. Is it because these projections were always in flux, and as a result she initially used an extremely low multiple? Ultimately MBX is an evolving story.   In my opinion its a fantastic story, that includes VTM which is not yet ...more  
Comment by RazeKreations on Dec 29, 2021 3:14pm
Mbxwatcher Totally agree with your statement.
Comment by wizzdumb on Dec 29, 2021 3:33pm
Yes, both articles were complete fluff and were either written by a bot or someone with no understanding of the company.  Does anyone have a link to the actual report or does she only release to IA subscribers?  Will be interesting to see KRC and/or ESpace updates. 
Comment by RazeKreations on Dec 29, 2021 3:49pm
Here is a link to the report from IA Capital I do not see her actual report anywhere. . https://www.cantechletter.com/2021/12/microbix-biosystems-should-continue-to-do-well-in-2022-says-ia-capital/
Comment by wizzdumb on Dec 29, 2021 4:30pm
Yeah that's just highlight of it, looks like you need to be a client to see the actual report. Thanks though. 
Comment by Launch64 on Dec 30, 2021 7:19am
https://apple.news/Azo6hbGy3RxqGnlHxzj9MEg
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities